Brief: Mirum Pharmaceuticals Announces Positive CHMP Opinion For Livmarli® (Maralixibat) Oral Solution For The Treatment Of Pfic In Patients Three Months Of Age And Older
31/05/2024 13:36
May 31 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O :
* MIRUM PHARMACEUTICALS ANNOUNCES POSITIVE CHMP OPINION FOR
LIVMARLI® (MARALIXIBAT) ORAL SOLUTION FOR THE TREATMENT OF PFIC
IN PATIENTS THREE MONTHS OF AGE AND OLDER
* MIRUM PHARMACEUTICALS INC -FOLLOWING CHMP AND COMP
OPINIONS, A
DECISION BY EUROPEAN COMMISSION IS EXPECTED IN Q3 OF 2024
* MIRUM PHARMACEUTICALS INC -ADDITIONALLY, LIVMARLI RECEIVED
FAVORABLE COMP OPINION RECOMMENDING MAINTENANCE OF ORPHAN DRUG
DESIGNATION IN PFIC
Source text for Eikon: ID:nBw1klsnSa
Further company coverage: MIRM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX